cardura
| Product dosage: 1mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 120 | $0.33 | $40.05 (0%) | 🛒 Add to cart |
| 180 | $0.31 | $60.07 $56.06 (7%) | 🛒 Add to cart |
| 270 | $0.29 | $90.10 $78.09 (13%) | 🛒 Add to cart |
| 360 | $0.26
Best per pill | $120.14 $94.11 (22%) | 🛒 Add to cart |
| Product dosage: 2mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.87 | $52.06 (0%) | 🛒 Add to cart |
| 90 | $0.79 | $78.09 $71.08 (9%) | 🛒 Add to cart |
| 120 | $0.76 | $104.12 $91.11 (12%) | 🛒 Add to cart |
| 180 | $0.72 | $156.18 $130.15 (17%) | 🛒 Add to cart |
| 270 | $0.70 | $234.27 $189.22 (19%) | 🛒 Add to cart |
| 360 | $0.67
Best per pill | $312.36 $241.28 (23%) | 🛒 Add to cart |
Cardura, known generically as doxazosin, is an alpha-1 adrenergic blocker primarily prescribed for managing hypertension and benign prostatic hyperplasia. It works by relaxing blood vessels and prostate/bladder neck smooth muscle. This monograph examines its clinical profile beyond standard prescribing information.
Key Components and Bioavailability Cardura
The active pharmaceutical ingredient is doxazosin mesylate, available in standard and extended-release formulations. The mesylate salt enhances water solubility while maintaining stability. Bioavailability reaches approximately 65% with extensive first-pass metabolism via CYP3A4. The extended-release formulation uses a gastrointestinal therapeutic system that controls dissolution over 24 hours, producing more stable plasma concentrations than the immediate-release version. Food doesn’t significantly affect absorption, though we typically recommend consistent administration relative to meals for habit formation.
Mechanism of Action Cardura: Scientific Substantiation
Doxazosin selectively blocks postsynaptic alpha-1 adrenergic receptors. In vascular smooth muscle, this inhibition prevents norepinephrine-induced vasoconstriction, reducing peripheral resistance. In prostatic tissue, it decreases tone in the bladder neck and prostate capsule. Interestingly, we’ve observed it also improves lipid profiles - reducing LDL and triglycerides while increasing HDL - though this isn’t an approved indication. The blood pressure reduction occurs within 1-2 hours post-dose, while BPH symptoms may take weeks to improve significantly.
Indications for Use: What is Cardura Effective For?
Cardura for Hypertension
As monotherapy or combination therapy for mild to moderate hypertension. Particularly effective in patients with metabolic syndrome components.
Cardura for Benign Prostatic Hyperplasia
Reduces urinary obstruction symptoms - improves flow rate, decreases residual volume, and alleviates nocturia. Not suitable for preventing BPH progression.
Off-Label Uses
Raynaud’s phenomenon, pheochromocytoma adjunct, and refractory CHF in select cases. These require careful risk-benefit assessment.
Instructions for Use: Dosage and Course of Administration
| Indication | Initial Dose | Maintenance Range | Administration |
|---|---|---|---|
| Hypertension | 1 mg daily | 2-8 mg daily | Morning or evening, consistent timing |
| BPH | 1 mg daily | 4-8 mg daily | Bedtime recommended initially |
Titrate no more frequently than every 1-2 weeks. First-dose hypotension risk necessitates evening administration when initiating therapy. We typically start older patients at 0.5 mg when possible, though this requires compounding.
Contraindications and Drug Interactions Cardura
Absolute contraindications include hypersensitivity to quinazolines and concomitant use with potent CYP3A4 inhibitors like ketoconazole in patients with hepatic impairment. Relative contraindications cover orthostatic hypotension predisposition and severe hepatic impairment.
Notable interactions:
- Phosphodiesterase-5 inhibitors: Profound hypotension risk
- Other antihypertensives: Additive effects
- CYP3A4 inducers: Reduced doxazosin concentrations
Pregnancy category C - use only if clearly needed. Not studied in breastfeeding.
Clinical Studies and Evidence Base Cardura
The ALLHAT trial (2000) raised important questions about doxazosin’s cardiovascular risk profile, showing higher heart failure incidence compared to chlorthalidone. However, subsequent meta-analyses have contextualized these findings - the risk appears primarily in specific patient subsets without adequate volume management.
For BPH, the MTOPS trial demonstrated doxazosin’s superiority over placebo in symptom improvement, though combination therapy with 5-alpha reductase inhibitors proved most effective for progression prevention. A 2018 Cochrane review confirmed moderate improvement in urinary symptoms versus placebo.
Comparing Cardura with Similar Products and Choosing Quality Medication
Versus tamsulosin: Cardura causes more hypotension but less retrograde ejaculation. Versus terazosin: Similar efficacy but longer half-life allows once-daily dosing. Generic doxazosin maintains bioequivalence to brand-name versions. We recommend checking for FDA approval status and manufacturer reputation when selecting generic alternatives.
Frequently Asked Questions (FAQ) about Cardura
What is the recommended course of Cardura to achieve results?
Hypertension control occurs within 1-2 weeks of optimal dosing. BPH symptom improvement may take 4-6 weeks. Long-term therapy required for maintained benefit.
Can Cardura be combined with beta-blockers?
Yes, with careful monitoring for orthostasis, particularly in elderly patients. Start low, go slow with titration.
Does Cardura cause weight gain?
Not typically - some patients actually experience mild weight loss, possibly related to reduced fluid retention.
Is tolerance development a concern with Cardura?
No significant tachyphylaxis documented - maintained efficacy demonstrated in studies up to 4 years.
Conclusion: Validity of Cardura Use in Clinical Practice
Cardura remains a valuable therapeutic option when selected appropriately. The hypertension application suits younger patients without significant cardiac risk factors, while BPH management works well in normotensive or controlled hypertensive men. The favorable metabolic profile provides additional benefit in diabetic patients. Careful patient selection and dose initiation minimize the orthostatic hypotension risk that concerned many clinicians post-ALLHAT.
I remember when we first started using doxazosin back in the late 90s - we were so enthusiastic about this new alpha-blocker. Had a patient, Mr. Henderson, 68-year-old with both moderate hypertension and bothersome BPH symptoms. His initial response was fantastic - blood pressure controlled, sleeping through the night for the first time in years. But then he missed a few doses during a vacation, restarted at his maintenance 4mg dose, and ended up in the ED with syncope. That was our hard lesson about the first-dose phenomenon recurrence after brief interruptions.
Our clinic actually developed a specific protocol after that incident - we now give patients a printed warning about re-initiation, and we keep a few 1mg tablets in their emergency supply. What’s interesting is that over the years, I’ve noticed the extended-release formulation seems to cause fewer of these dramatic hypotensive episodes, though the evidence is mostly anecdotal.
We had this debate in our department last year - one of our newer physicians wanted to move all BPH patients to tamsulosin, arguing better tolerability. But I’ve had several patients, like 72-year-old Carl Jefferson, who failed multiple other alpha-blockers due to retrograde ejaculation but did perfectly fine on Cardura. His quality of life improvement was dramatic - he told me last visit he’s able to take road trips again without constant bathroom mapping.
The lipid effects are something we don’t talk about enough. I’ve followed Sarah Mitchell, 58, with mixed hyperlipidemia and mild hypertension - her LDL dropped 15% on doxazosin monotherapy. Not enough to avoid a statin, but a nice ancillary benefit.
What surprised me was discovering how many urologists weren’t aware of the blood pressure effects when co-prescribing with ED medications. We had a close call with a 65-year-old who took sildenafil 24 hours after his doxazosin dose - his BP dropped to 80/50. Now we have a mandatory counseling point about this interaction.
Long-term follow-up has shown me that the patients who do best are those we start low and titrate slowly. James Wilson, now 74, has been on Cardura for 8 years for his BPH. His dose has remained at 2mg daily - never needed escalation, symptoms still well-controlled. Meanwhile, some colleagues push to maximum dosing quickly, then wonder why patients complain of dizziness.
The satisfaction surveys in our practice show that when properly managed, doxazosin provides good quality of life - better than many newer, more expensive medications. David Chen, 61, put it perfectly: “This little pill gives me back my sleep and my dignity.” That’s why, despite the newer options, Cardura remains in my top choices for appropriate patients.